| protein
| IFN-gamma ( |
|
IFN-gamma receptor, IFN-gamma R ( |
|
synaptophysin, Syp ( |
|
AT1 receptor ( |
|
beta c chain of the GM-CSF receptor ( |
|
erythropoietin receptor, EPOR ( |
|
c-kit proto-oncogene ( |
|
PP2A, P13K, and Yes ( |
|
interleukin-12 receptor subunits beta1 and beta2 ( |
|
signal transducer and activator of transcription 5, STAT5 ( |
|
SHC (Src homology 2 domain containing) transforming protein, Shc ( |
|
signal transducer and activator of transcription 3, STAT3 ( |
|
SH2-Bbeta ( |
|
midkine-receptor ( |
|
tec protein tyrosine kinase, TEC ( |
|
insulin receptor, IR and the insulin-like growth factor-1 receptor, IGF1 ( |
|
tumor necrosis factor receptor 1, TNFR1 ( |
|
interleukin-5 (IL-5) receptor alpha and betac ( |
|
p125 focal adhesion kinase, FAK ( |
|
growth factor receptor-bound protein 10, Grb10 ( |
|
interleukin-12 receptor beta 2, IL-12R beta 2 ( |
|
cytokine-inducible SH2 protein 3, CIS3 ( |
|
growth hormone receptor, GHR ( |
|
chemokine (C-X-C motif) receptor 4, CXCR4 ( |
|
Skb1 and Hsl7p ( |
|
SH2-Containing protein tyrosine phosphatase-1, SHP-1 ( |
|
thyroid stimulating hormone receptor, TSHR ( |
|
SIRPalpha ( |
|
box 1-like motif in the cytoplasmic tail of CTLA-4 molecule ( |
|
cytokine receptor-like molecule 2, CRLM-2 ( |
|
signal transducing adaptor molecule (SH3 domain and ITAM motif) 1, STAM1 and signal transducing adaptor molecule (SH3 domain and ITAM motif) 2, STAM2 ( |
|
hTid-1(S) or hTid-1(L) ( |
|
protein tyrosine phosphatase, non-receptor type 1B, PTP1B ( |
|
protein tyrosine phosphatase-PEST, PTP-PEST ( |
|
G protein-coupled AngII type 1, AT(1) and protein tyrosine kinase 2 beta, PYK2B ( |
|
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian), ERBB2 ( |
|
suppressor of cytokine signaling 1, SOCS1 ( |
|
Hes1 and Hes5 ( |
|
FABP4 in a fatty acid-dependent manner |
|
beta subunit of IFNgamma receptor and PKCepsilon |
|
VHL is a SOCS1-cooperative negative regulator of JAK2 |
|
oncogenic LCK and JAK2 may utilize different mechanisms to upregulate LMO2 levels during oncogenic transformation |
|
is a novel regulator of the GABA transporter SLC6A12 (the kinase up-regulates the carrier presumably by enhancing the insertion of carrier protein into the cell membrane) |
|
JAK2 is a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in chronic eosinophilic leukemia (CEL) (pMID: 22523564) |
|
JAK2 down-regulates CLCN2 activity and thus counteracts Cl(-) exit, an effect which may impact on cell volume regulation |
|
contributes to the regulation of the inositol transporter (SLC5A3) |
|
may similarly contribute to the stimulating effect of Angiotensin II on Na+ coupled phosphate transport and insertion of SLC34A1 protein into the proximal renal tubular brush border membrane |
|
CCDC80 is a JAK2-binding partner |
|
JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein NIN |
|
NK cell activation and secretion of IFNG1 results in activation of JAK1, JAK2 and STAT1 in tumor cells, resulting in rapid up-regulation of CD274 expression |
|
SOCS1 negatively regulates IFNG1 signaling pathway (and other pathways) by directly inhibiting JAK1, JAK2 |
